CAMBRIDGE, Mass., May 10 /PRNewswire-FirstCall/ --
Biogen, Inc. (Nasdaq: BGEN) announced today that Michael D. Kowolenko, Ph.D.,
has been appointed Vice President, Global Quality. Dr. Kowolenko will
supervise the company's worldwide Quality Operations. He reports to Sylvie
Gregoire, Pharm.D., Executive Vice President, Technical Operations.
(Photo: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
Dr. Gregoire said, "Michael brings to this new position expertise in
quality assurance, research and drug development. He will be instrumental in
ensuring that Biogen's manufacturing capability continues to be world-class in
quality and scale. Biogen has a record of exceeding industry standards in our
ability to build and validate our manufacturing resources. We have also
maintained the highest quality and efficiency in delivering products to our
customers around the world. I am confident that Michael's experience will be
a great asset to Biogen in our continued drive to lead the way in biologics
production."
Dr. Kowolenko joins Biogen from Bayer Corporation in Clayton, NC where he
was most recently Vice President of Quality Assurance for the Biological
Products Business Unit. During his nine years at Bayer, he held several
positions, including Director of Research for Biologic Products, Department
Head for Preclinical Development and Senior Scientist for Clinical Chemistry
and Preclinical Biology. Prior to joining Bayer, from 1989-1993, Dr.
Kowolenko was at Bristol-Myers Squibb in Syracuse, New York where he was a
Supervisor and then Manager of Immunotoxicology. Before joining the industry,
he held several academic positions, including Assistant Professor in the
Department of Medicine and the Department of Microbiology and Immunology at
Albany Medical College.
Dr. Kowolenko received a Bachelor of Science in Pharmacy, a Master of
Science in Pharmacology and a Ph.D. in Immunology from Northeastern University
in Boston.
About Biogen
Biogen, Inc., winner of the U.S. National Medal of Technology, is a
biotechnology company principally engaged in discovering and developing drugs
for human healthcare through genetic engineering. Headquartered in Cambridge,
MA, the Company's revenues are generated from U.S. and European sales of
AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of multiple
sclerosis, (Please see full prescribing information at
http://www.avonex.com.), and from the worldwide sales by licensees of a number
of products, including alpha interferon and hepatitis B vaccines and
diagnostic products. Biogen's research and development activities are focused
on novel products to treat inflammatory and autoimmune diseases, neurological
diseases, cancer, fibrosis and congestive heart failure. The Company
maintains active clinical research programs in protein therapeutics, small
molecules, genomics and gene therapy. For copies of press releases and
additional information about the Company, please consult Biogen's homepage on
the World Wide Web at http://www.biogen.com.
Media Contact:
Amy Brockelman
Manager, Public Affairs
Biogen, Inc.
Tel: (617) 679-3860
Investment Community Contact:
Christina Dillon
Manager, Investor Relations
Biogen, Inc.
Tel: (617) 679-2521
SOURCE Biogen, Inc.
 back to top
Related links:
http://www.biogen.com
Company News On-Call:
http://www.prnewswire.com/comp/101550.html
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
CONTACT:
Amy Brockelman, Manager, Public Affairs,
+1-617-679-3860, or Christina Dillon, Manager, Investor
Relations, +1-617-679-2521, both of Biogen, Inc.
|
